Exact Sciences (NASDAQ:EXAS) reported quarterly earnings results on February 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.21, missing the consensus estimate of $0.08 by $0.29 per share. Revenue came in at $878.4M, beating the estimate of $860.7M.
Exact Sciences's stock moved following the earnings release. The stock currently trades at $103.24 with a market capitalization of $19.2B.